IP Library Granted Patent US 12,396,965
Granted Patent B2
US 12,396,965 · App. 18/659,232 · Granted Aug 26, 2025

Putrescine topical barrier formulation

Inventor: Ghislain Vivier (St-Lazare, CA)
Assignee: VIVIER CANADA INC.
A61K31/132A61K9/0014A61K31/205A61K47/44A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,396,965
App. No.
18/659,232
Granted
Aug 26, 2025
Kind
B2
Abstract

The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging.

Claims (18)

1. A topical water free barrier composition comprising: (i) a primary aliphatic lower-alkyl (C1-5) polyamine in a concentration of between about 0.1% w/w to about 1% w/w; (ii) a phospholipid to encapsulate the primary polyamine, the phospholipid being cocamidopropyl PG-dimonium chloride phosphate in a concentration of between about 3% w/w and about 6% w/w; (iii) petroleum jelly in a concentration of between about 25% w/w and 65% w/w; and (iv) mineral oil in a concentration of between about 30% w/w and about 45% w/w.

2. The barrier composition of claim 1 , wherein the polyamine is putrescine or dansylcadaverine.

3. The barrier composition of claim 1 , wherein the polyamine is putrescine.

4. The barrier composition of claim 3 , wherein the putrescine is in a concentration of between about 0.4% w/w and about 0.8% w/w.

5. The barrier composition of claim 1 , wherein the petroleum jelly is in a concentration of about 45% w/w.

6. The barrier composition of claim 1 , wherein the mineral oil is in a concentration of about 35% w/w.

7. The barrier composition of claim 1 , wherein the cocamidopropyl PG-dimonium chloride phosphate is in a concentration of about 4% w/w.

8. The barrier composition of claim 1 , further comprising (i) paraffin; (ii) lanolin oil; (iii) a lipophilic Vitamin C derivative; (iv) one or more humectants; and/or (v) bisabolol.

9. The barrier composition of claim 8 , wherein the paraffin is in a concentration of between about 3% w/w and 15% w/w.

10. The barrier composition of claim 8 , wherein the lanolin oil is in a concentration of between about 3% w/w and 6% w/w.

11. The barrier composition of claim 8 , wherein the lipophilic Vitamin C derivative is in a concentration of between about 0.1% w/w and 10% w/w.

12. The barrier composition of claim 8 , wherein the lipophilic Vitamin C derivative comprises 3-O-Ethyl Ascorbic Acid (3-O-EAA).

13. The barrier composition of claim 12 , wherein the 3-O-EAA is in a concentration of about 0.5% w/w.

14. The barrier composition of claim 8 , wherein the one or more humectants is(are) in a concentration of between about 0.5% w/w and 3% w/w.

15. The barrier composition of claim 8 , wherein the one or more humectants comprise(s) glycerin, vitamin B5 or a combination thereof.

16. The barrier composition of claim 15 , wherein the one or more humectants comprise(s) about 1% w/w of the glycerin and about 1% w/w of the Vitamin B5.

17. The barrier composition of claim 8 , wherein the bisabolol is in a concentration of between about 0.1% w/w and 1% w/w.

18. A method of using the barrier composition defined in claim 1 , for (i) treating of skin inflammation, treating skin irritation and/or reducing skin's signs of aging; (ii) promoting wound healing; or (iii) reducing formation of hypertrophic scar tissue, comprising topically administering the barrier composition on a subject.

Assignments (1)
NUNC PRO TUNC ASSIGNMENT Recorded May 9, 2024
From: VIVIER, GHISLAIN, MR.
To: VIVIER CANADA INC.
Reel/Frame 067360/0204 →
Continuity (5)
Continuation 17302527 · May 5, 2021
Continuation 16883864 · May 26, 2020
Continuation 16349030
Provisional Application 62443158 · Jan 6, 2017
Related Publication 20240293340A1 · Sep 5, 2024
References Cited (26)
US 5885982A · Dolynchuk et al. · 1999 [cited by applicant]
US 20200281872A1 · Vivier · 2020 [cited by applicant]
CA 2706630A1 · 2009 [cited by applicant]
EP 2604254B1 · 2016 [cited by applicant]
WO 9951213A2 · 1999 [cited by applicant]
WO 2006048671A1 · 2006 [cited by applicant]
WO 2012175686A2 · 2012 [cited by applicant]
Dolynchuk et al., Effect of putrescine on tissue transglutaminase activity in wounds: decreased breaking strength and increased matrix fucoprotein solubility, plastic and reconstructive surgery, 1994, pp. 567-573, vol. … [cited by applicant]
Dolynchuk, Inhibition of tissue transglutaminase and e (gamma-glutamyl) lysine cross-linking in human hypertrophic scar, Wound Repair and Regeneration, 1996, pp. 16-20, vol. 4. [cited by applicant]
Dolynchuk et al., Topical putrescine (Fibrostat) in treatment of hypertrophic scars: phase II study, Plastic and Reconstructive Surgery, 1996, p. 117-23; discussion p. 124-5, vol. 97. [cited by applicant]
International Searching Authority, International search report and written opinion, Mar. 21, 2018, pp. 1-13, Canada. [cited by applicant]
Jeong et al., Resurfacing of pitted facial acne scars with a long-pulsed er: YAG Laser, The American Society for Dermatologic Sergery Inc., Feb. 2001, pp. 107-110. [cited by applicant]
Lynde, Moisturizers: What they are and how they work, Skin Therapy Letter, Dec. 2001, https://www.skintherapyletter.com/eczema/how-moisturizers-work/, vol. 6 No. 13. [cited by applicant]
MacKay et al., Nutritional Support for Wound Healing, Alternative Medicine Review, 2003, pp. 359-377, vol. 8 No. 4. [cited by applicant]
Rowe et al., Handbook of Pharmaceutical Excipients sixth edition, The Pharmaceutical Press and American Pharmacists Association, 2009, 917 pages. [cited by applicant]
Traikovitch, Use of Topical Ascorbic Acid and Its Effects on Photodamaged Skin Topography, Arch Otolaryngol head neck Surg., Oct. 1999, pp. 1091-1098, vol. 125. [cited by applicant]
Vivier, V-STAT Advanced Scar Gel (30 ml), Vivier Pharma Inc., May 24, 2017, https://www.vivierpharma.com/en_US/V-stat-advanced-scar-gel-30ml. [cited by applicant]
Vivier, V-STAT TM, Vivier Pharma Inc., May 24, 2017, https://www.vivierpharma.com/en_US/v-stat/. [cited by applicant]
Vivier, Vivier Pharma launches V-STAT Advanced Scar Gel, PR Web, May 24, 2017, https://www.prweb.com/releases/2017/05/prweb14362706.htm. [cited by applicant]
Spec-Chem Ind, China, 2014, pp. 1-2. (Year: 2014). [cited by applicant]
Aprahamian M. et al., “Effects of supplemental pantothenic acid on wound healing: experimental study in rabbit”, Am J Clin Nutr. Mar. 1985: 41 (3):578-89 (abstract only is attached). (Year: 1985). [cited by applicant]
USPTO Restriction Requirement dated Jul. 2, 2020 in U.S. Appl. No. 16/883,864. [cited by applicant]
USPTO Non Final Rejection dated Nov. 12, 2020 in U.S. Appl. No. 16/883,864. [cited by applicant]
USPTO Restriction Requirement dated Aug. 10, 2022 in U.S. Appl. No. 17/302,527. [cited by applicant]
USPTO Non Final Rejection dated Jan. 19, 2023 in U.S. Appl. No. 17/302,527. [cited by applicant]
USPTO Final Rejection dated Dec. 13, 2023 in U.S. Appl. No. 17/302,527. [cited by applicant]